Selected High-Risk Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy for Adjuvant Chemotherapy: A Multi-Institutional Retrospective Study

被引:15
|
作者
Ikeda, Masaomi [1 ,2 ]
Matsumoto, Kazumasa [1 ]
Hirayama, Takahiro [1 ]
Koguchi, Dai [3 ]
Murakami, Yasukiyo [4 ]
Matsuda, Daisuke [5 ]
Okuno, Norihiko [6 ]
Utsunomiya, Takuji [4 ]
Taoka, Yoshinori [3 ]
Irie, Akira [2 ]
Iwamura, Masatsugu [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Urol, Sagamihara, Kanagawa, Japan
[2] Kitasato Univ, Kitasato Inst Hosp, Dept Urol, Tokyo, Japan
[3] Kitasato Univ, Med Ctr, Dept Urol, Saitama, Japan
[4] Sagamihara Kyodo Hosp, Kanagawa Prefectural Federat Agr Cooperat Hlth &, Dept Urol, Sagamihara, Kanagawa, Japan
[5] Higashiyamato Hosp, Dept Urol, Tokyo, Japan
[6] Natl Hosp Org Sagamihara Hosp, Dept Urol, Sagamihara, Kanagawa, Japan
关键词
Lymph node status; Lymphovascular invasion; pT stage; Surgical margin; Tumor grade; UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; MICROSATELLITE INSTABILITY; TUMORS; OUTCOMES;
D O I
10.1016/j.clgc.2017.10.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the efficacy of adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma (UTUC) and determined those who qualified for AC. In multivariate analyses, 5 factors (>= pT3, pN+, G3, lymphovascular invasion, positive surgical margin) were independently predictive of poorer survival. Having more than 3 risk factors defined the high-risk group. AC was associated with improved survival in high-risk UTUC. Background: No definitive evidence exists regarding use of adjuvant chemotherapy (AC) for high-risk cases after radical nephroureterectomy (RNU), and the benefit of AC remains controversial. The aims of this study were to evaluate the efficacy of AC in patients with upper tract urothelial carcinoma (UTUC) and to determine those who qualified for AC. Patients and Methods: From 1990 to 2015, 449 patients with nonmetastatic UTUC underwent RNU at 6 Kitasato University-affiliated hospitals. Eight patients who received neoadjuvant chemotherapy were excluded from this study. One hundred patients (23%) received platinum-based AC for a median of 3 courses. Disease-free survival and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Multivariate analyses were performed with the Cox proportional hazards regression model, controlling for the effects of clinicopathological factors. Results: The median age was 69 years, and the median follow-up period was 35.7 months. In multivariate analyses, factors independently predictive of poorer survival included pT stage (>= pT3), lymph node status (pN+), tumor grade (Grade 3), lymphovascular invasion, and soft tissue surgical margin. For the risk stratification model, patients were categorized into 3 groups on the basis of these 5 risk factors. In the high-risk group (at least 3 risk factors, 83 patients), 41 patients (49%) were treated with AC, and the 5-year CSS rate was higher in the AC group compared with the non-AC group (P = .02). Conclusion: Having more than 3 risk factors defined the high-risk group among UTUC patients after RNU. AC was associated with improved CSS in patients with high-risk UTUC. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:E669 / E675
页数:7
相关论文
共 50 条
  • [1] Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study
    Nakagawa, Tohru
    Komemushi, Yoshimitsu
    Kawai, Taketo
    Otsuka, Masafumi
    Miyakawa, Jimpei
    Uemura, Yukari
    Kanatani, Atsushi
    Taguchi, Satoru
    Naito, Akihiro
    Suzuki, Motofumi
    Nishimatsu, Hiroaki
    Hirano, Yoshikazu
    Tanaka, Yoshinori
    Matsumoto, Akihiko
    Miyazaki, Hideyo
    Fujimura, Tetsuya
    Fukuhara, Hiroshi
    Kume, Haruki
    Igawa, Yasuhiko
    Homma, Yukio
    WORLD JOURNAL OF UROLOGY, 2017, 35 (10) : 1569 - 1575
  • [2] Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study
    Tohru Nakagawa
    Yoshimitsu Komemushi
    Taketo Kawai
    Masafumi Otsuka
    Jimpei Miyakawa
    Yukari Uemura
    Atsushi Kanatani
    Satoru Taguchi
    Akihiro Naito
    Motofumi Suzuki
    Hiroaki Nishimatsu
    Yoshikazu Hirano
    Yoshinori Tanaka
    Akihiko Matsumoto
    Hideyo Miyazaki
    Tetsuya Fujimura
    Hiroshi Fukuhara
    Haruki Kume
    Yasuhiko Igawa
    Yukio Homma
    World Journal of Urology, 2017, 35 : 1569 - 1575
  • [3] Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity
    Luo, Yong
    Feng, Bingfu
    Wei, Dechao
    Han, Yili
    Li, Mingchuan
    Zhao, Jiahui
    Lin, Yunhua
    Hou, Zhu
    Jiang, Yongguang
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [4] Adjuvant chemotherapy for high-risk upper tract urothelial carcinoma
    Chang, Y. H.
    Lin, C. C.
    Hsiao, P. J.
    Chen, G. H.
    Huang, C. P.
    Wu, H. C.
    Yang, C. R.
    Chang, C. H.
    Yeh, S. P.
    BJU INTERNATIONAL, 2015, 115 : 16 - 17
  • [5] Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity
    Yong Luo
    Bingfu Feng
    Dechao Wei
    Yili Han
    Mingchuan Li
    Jiahui Zhao
    Yunhua Lin
    Zhu Hou
    Yongguang Jiang
    Scientific Reports, 10
  • [6] Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience
    Riccardo Campi
    Juliette Cotte
    Francesco Sessa
    Thomas Seisen
    Riccardo Tellini
    Daniele Amparore
    Nicola Mormile
    Aurélien Gobert
    Andrea Mari
    Francesco Porpiglia
    Sergio Serni
    Andrea Minervini
    Morgan Rouprêt
    World Journal of Urology, 2019, 37 : 2303 - 2311
  • [7] Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience
    Campi, Riccardo
    Cotte, Juliette
    Sessa, Francesco
    Seisen, Thomas
    Tellini, Riccardo
    Amparore, Daniele
    Mormile, Nicola
    Gobert, Aurelien
    Mari, Andrea
    Porpiglia, Francesco
    Serni, Sergio
    Minervini, Andrea
    Roupret, Morgan
    WORLD JOURNAL OF UROLOGY, 2019, 37 (11) : 2303 - 2311
  • [8] C-REACTIVE PROTEIN INDEPENDENTLY PREDICTS THE PROGNOSIS OF PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA TREATED WITH RADICAL NEPHROURETERECTOMY: A MULTI-INSTITUTIONAL STUDY
    Obata, Jun
    Kikuchi, Eiji
    Tanaka, Nobuyuki
    Ishioka, Katsura
    Shirotake, Suguru
    Matsumoto, Kazuhiro
    Kobayashi, Hiroaki
    Miyazaki, Yasumasa
    Ide, Hiroki
    Hayakawa, Nozomi
    Ito, Yujiro
    Kanao, Kent
    Miyajima, Akira
    Momma, Tetsuo
    Nakagawa, Ken
    Ueno, Munehisa
    Oya, Mototsugu
    JOURNAL OF UROLOGY, 2013, 189 (04): : E286 - E287
  • [9] The Predictive Value of C-reactive Protein for Prognosis in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Multi-institutional Study
    Tanaka, Nobuyuki
    Kikuchi, Eiji
    Shirotake, Suguru
    Kanao, Kent
    Matsumoto, Kazuhiro
    Kobayashi, Hiroaki
    Miyazaki, Yasumasa
    Ide, Hiroki
    Obata, Jun
    Hoshino, Katsura
    Hayakawa, Nozomi
    Ito, Yujiro
    Kosaka, Takeo
    Kodaira, Kiichiro
    Oyama, Masafumi
    Miyajima, Akira
    Momma, Tetsuo
    Nakagawa, Ken
    Ueno, Munehisa
    Oya, Mototsugu
    EUROPEAN UROLOGY, 2014, 65 (01) : 227 - 234
  • [10] The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy
    Pinar, Ugo
    Calleris, Giorgio
    Grobet-Jeandin, Elisabeth
    Grande, Pietro
    Benamran, Daniel
    Thibault, Constance
    Gontero, Paolo
    Roupret, Morgan
    Seisen, Thomas
    WORLD JOURNAL OF UROLOGY, 2023, 41 (11) : 3205 - 3230